Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Dimerix Limited ( (AU:DXB) ) has issued an announcement.
Dimerix Limited has announced the application for quotation of 41,710 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of an employee incentive scheme, indicating a strategic effort to motivate and retain talent within the company, which could positively impact its operational capabilities and market positioning.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited is a company operating in the biotechnology industry, focusing on the development of innovative therapies. The company is primarily engaged in creating treatments for unmet medical needs, with a market focus on rare and chronic diseases.
Average Trading Volume: 2,006,601
Technical Sentiment Signal: Buy
Current Market Cap: A$312.1M
See more insights into DXB stock on TipRanks’ Stock Analysis page.